Epstein-Barr Virus Down-Regulates Tumor Suppressor DOK1 Expression

PLoS Pathogens

Volumn 10, Issue 5, 2014, Pages

  Siouda, Maha ^a   Frecha, Cecilia ^a   Accardi, Rosita ^a   Yue, Jiping ^a,e   Cuenin, Cyrille ^a   Gruffat, Henri ^b,c,d   Manet, Evelyne ^b,c,d   Herceg, Zdenko ^a   Sylla, Bakary S ^a   Tommasino, Massimo ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^c UNIVERSITÉ DE LYON   (France)

^d CNRS   (France)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; DOK1 PROTEIN, HUMAN; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; PHOSPHOPROTEIN; RNA BINDING PROTEIN;

B LYMPHOCYTE; CELL CULTURE; DNA METHYLATION; DOWN REGULATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PRIMARY CELL CULTURE; TUMOR SUPPRESSOR GENE; VIROLOGY; VIRUS CELL TRANSFORMATION;

B-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; DNA METHYLATION; DNA-BINDING PROTEINS; DOWN-REGULATION; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HERPESVIRUS 4, HUMAN; HUMANS; PHOSPHOPROTEINS; PRIMARY CELL CULTURE; RNA-BINDING PROTEINS; VIRAL MATRIX PROTEINS;

EID: 84901664088     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004125     Document Type: Article

References (46)

1. Mashima R, Hishida Y, Tezuka T, Yamanashi Y, (2009) The roles of Dok family adapters in immunoreceptor signaling. Immunol Rev 232: 273-285.
2. Di Cristofano A, Niki M, Zhao M, Karnell FG, Clarkson B, et al. (2001) p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med 194: 275-284.
3. Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, et al. (2010) Identification of DOK genes as lung tumor suppressors. Nature Genetics 42: 216-U227.
4. Yasuda T, Shirakata M, Iwama A, Ishii A, Ebihara Y, et al. (2004) Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia. J Exp Med 200: 1681-1687.
5. Yasuda T, Bundo K, Hino A, Honda K, Inoue A, et al. (2007) Dok-1 and Dok-2 are negative regulators of T cell receptor signaling. Int Immunol 19: 487-495.
6. Nelms K, Snow AJ, Noben-Trauth K, (1998) Dok1 encoding p62(dok) maps to mouse chromosome 6 and human chromosome 2 in a region of translocation in chronic lymphocytic leukemia. Genomics 53: 243-245.
7. Janas JA, Van Aelst L, (2011) Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation. Mol Cell Biol 31: 2552-2565.
8. Lee S, Roy F, Galmarini CM, Accardi R, Michelon J, et al. (2004) Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia. Oncogene 23: 2287-2297.
9. Saulnier A, Vaissiere T, Yue J, Siouda M, Malfroy M, et al. (2012) Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers. Int J Cancer 130: 2484-2494.
10. Lambert MP, Paliwal A, Vaissiere T, Chemin I, Zoulim F, et al. (2011) Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 54: 705-715.
11. Balassiano K, Lima S, Jenab M, Overvad K, Tjonneland A, et al. (2011) Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Cancer Lett 311: 85-95.
12. Young LS, Rickinson AB, (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.
13. Straus SE, (1988) The chronic mononucleosis syndrome. J Infect Dis 157: 405-412.
14. Epstein MA, Achong BG, Barr YM, (1964) Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 1: 702-703.
15. Flavell KJ, Murray PG, (2000) Hodgkin's disease and the Epstein-Barr virus. Mol Pathol 53: 262-269.
16. Carbone A, Gloghini A, Dotti G, (2008) EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 13: 577-585.
17. Matsusaka K, Kaneda A, Nagae G, Ushiku T, Kikuchi Y, et al. (2011) Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res 71: 7187-7197.
18. Farrell PJ, (1995) Epstein-Barr virus immortalizing genes. Trends Microbiol 3: 105-109.
19. Bornkamm GW, Hammerschmidt W, (2001) Molecular virology of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 356: 437-459.
20. Kaye KM, Izumi KM, Kieff E, (1993) Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 90: 9150-9154.
21. Cahir McFarland ED, Izumi KM, Mosialos G, (1999) Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. Oncogene 18: 6959-6964.
22. Eliopoulos AG, Young LS, (2001) LMP1 structure and signal transduction. Semin Cancer Biol 11: 435-444.
23. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, et al. (1995) The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80: 389-399.
24. Roberts ML, Cooper NR, (1998) Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 240: 93-99.
25. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS, (1999) Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274: 16085-16096.
26. Huen DS, Henderson SA, Croom-Carter D, Rowe M, (1995) The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10: 549-560.
27. Eliopoulos AG, Blake SM, Floettmann JE, Rowe M, Young LS, (1999) Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol 73: 1023-1035.
28. Dawson CW, Port RJ, Young LS, (2012) The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol 22: 144-153.
29. Siouda M, Yue J, Shukla R, Guillermier S, Herceg Z, et al. (2012) Transcriptional regulation of the human tumor suppressor DOK1 by E2F1. Mol Cell Biol 32: 4877-4890.
30. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, et al. (1996) Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 16: 7098-7108.
31. Izumi KM, Kieff ED, (1997) The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci U S A 94: 12592-12597.
32. Atkinson PG, Coope HJ, Rowe M, Ley SC, (2003) Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-kappa B2 p100 to p52. J Biol Chem 278: 51134-51142.
33. Niki M, Di Cristofano A, Zhao M, Honda H, Hirai H, et al. (2004) Role of Dok-1 and Dok-2 in leukemia suppression. J Exp Med 200: 1689-1695.
34. Lee S, Huang H, Niu Y, Tommasino M, Lenoir G, et al. (2007) Dok1 expression and mutation in Burkitt's lymphoma cell lines. Cancer Lett 245: 44-50.
35. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, et al. (2009) Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5: e1000492.
36. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, et al. (2009) Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 69: 2766-2774.
37. Sakuma K, Chong JM, Sudo M, Ushiku T, Inoue Y, et al. (2004) High-density methylation of p14ARF and p16INK4A in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 112: 273-278.
38. Paschos K, Allday MJ, (2010) Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol 18: 439-447.
39. Urist M, Tanaka T, Poyurovsky MV, Prives C, (2004) p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 18: 3041-3054.
40. Zhang HJ, Li WJ, Yang SY, Li SY, Ni JH, et al. (2009) 8-Chloro-adenosine-induced E2F1 promotes p14ARF gene activation in H1299 cells through displacing Sp1 from multiple overlapping E2F1/Sp1 sites. J Cell Biochem 106: 464-472.
41. Accardi RFI, Gruffat H, Mariggiò G, Le Calvez-Kelm F, Voegele C, Bartosch B, Hernandez-Vargas H, McKay J, Sylla BS, Manet E, Tommasino M, (2013 Mar) Epstein- Barr virus transforming protein LMP-1 alters B cells gene expression by promoting accumulation of the oncoprotein ΔNp73α. PLoS Pathog 9 (3).
42. Lee S, Andrieu C, Saltel F, Destaing O, Auclair J, et al. (2004) IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation. Proc Natl Acad Sci U S A 101: 17416-17421.
43. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W, (1998) Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A 95: 8245-8250.
44. Delecluse HJ, Pich D, Hilsendegen T, Baum C, Hammerschmidt W, (1999) A first-generation packaging cell line for Epstein-Barr virus-derived vectors. Proc Natl Acad Sci U S A 96: 5188-5193.
45. Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, et al. (2003) Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein-Barr virus. Cancer Research 63: 2982-2989.
46. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, et al. (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 89: 1827-1831.